Live data · NADAC + Part D CY24 · reviewed daily

Erythromycin and Benzoyl Peroxide (Benzamycin)

Macrolide class · 1 generic manufacturer · 1 ANDAs filed at FDA.

First FDA approval1984-10-26
Generic availableYes · 1 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.949/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.44
Across all dosage forms in distribution.
Highest NADAC
$1.93
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Erythromycin and Benzoyl Peroxide used for?

Erythromycin and Benzoyl Peroxide is a Macrolide medication tracked in Medicare Part D.

Is there a generic for Erythromycin and Benzoyl Peroxide?

Yes. 1 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Erythromycin and Benzoyl Peroxide?

Across 329 Part D plans, Erythromycin and Benzoyl Peroxide averages $1.44/unit (NADAC). Lowest available: $0.949/unit. Highest in distribution: $1.93/unit.

Is Erythromycin and Benzoyl Peroxide on the FDA shortage list?

No. Erythromycin and Benzoyl Peroxide is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Macrolide3 alternatives in D1
01
Erythromycin
Brand: ERY-TAB
$0.348Lowest NADAC
15Generic mfrs
CY24 Part D spend
Compare →
02
$0.905Lowest NADAC
4Generic mfrs
$5.3MCY24 Part D spend
Compare →
03
$0.348Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh14 Jul 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.